NASDAQ:MDWD MediWound (MDWD) Stock Price, News & Analysis → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free MDWD Stock Alerts $16.31 +0.27 (+1.68%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$15.84▼$16.8950-Day Range$14.00▼$19.2752-Week Range$7.10▼$19.86Volume38,686 shsAverage Volume45,703 shsMarket Capitalization$151.42 millionP/E RatioN/ADividend YieldN/APrice Target$32.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get MediWound alerts: Email Address MediWound MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside96.2% Upside$32.00 Price TargetShort InterestHealthy3.42% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.93) to ($1.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.16 out of 5 starsMedical Sector611th out of 928 stocksMedicinals & Botanicals Industry4th out of 11 stocks 3.5 Analyst's Opinion Consensus RatingMediWound has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMediWound has only been the subject of 1 research reports in the past 90 days.Read more about MediWound's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.42% of the float of MediWound has been sold short.Short Interest Ratio / Days to CoverMediWound has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MediWound has recently increased by 3.14%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMediWound does not currently pay a dividend.Dividend GrowthMediWound does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MDWD. Previous Next 3.0 News and Social Media Coverage News SentimentMediWound has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for MediWound this week, compared to 1 article on an average week.Search Interest2 people have searched for MDWD on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added MediWound to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MediWound insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.20% of the stock of MediWound is held by insiders.Percentage Held by Institutions46.83% of the stock of MediWound is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MediWound's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MediWound are expected to grow in the coming year, from ($1.93) to ($1.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MediWound is -11.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MediWound is -11.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMediWound has a P/B Ratio of 6.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about MediWound's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media[Urgent!] Generational Wealth GameplanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About MediWound Stock (NASDAQ:MDWD)MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.Read More MDWD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDWD Stock News HeadlinesMay 30 at 8:24 AM | americanbankingnews.comMediWound (NASDAQ:MDWD) Rating Reiterated by HC WainwrightMay 29 at 3:56 PM | finanznachrichten.deMediWound Ltd.: MediWound Reports First Quarter 2024 Financial Results and Provides Company UpdateMay 29 at 1:08 PM | investorplace.comMDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q1 2024May 29 at 7:00 AM | globenewswire.comMediWound Reports First Quarter 2024 Financial Results and Provides Company UpdateMay 28, 2024 | money.usnews.comMediWound LtdMay 28, 2024 | msn.comMediWound Q1 2024 Earnings PreviewMay 27, 2024 | americanbankingnews.comMediWound (MDWD) Scheduled to Post Earnings on WednesdayMay 22, 2024 | globenewswire.comMediWound to Report First Quarter 2024 Financial ResultsMay 13, 2024 | finance.yahoo.comInvestors in MediWound (NASDAQ:MDWD) have seen decent returns of 65% over the past yearApril 25, 2024 | globenewswire.comMediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care ConferencesApril 17, 2024 | finance.yahoo.comStrength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?March 24, 2024 | finance.yahoo.comMediWound Ltd. (NASDAQ:MDWD) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?March 23, 2024 | seekingalpha.comMediWound Ltd. (MDWD) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | markets.businessinsider.comMediwound Poised for Growth: A Strong Buy Recommendation Amidst Promising Prospects and Strategic ExpansionMarch 21, 2024 | investorplace.comMDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q4 2023March 21, 2024 | msn.comMediWound reports mixed Q4 results; initiates FY24 outlookMarch 21, 2024 | chron.comMediWound: Q4 Earnings SnapshotMarch 21, 2024 | globenewswire.comMediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company UpdateMarch 20, 2024 | msn.comMediWound Q4 2023 Earnings PreviewMarch 14, 2024 | globenewswire.comMediWound to Report Fourth Quarter and Full Year 2023 Financial ResultsMarch 7, 2024 | finance.yahoo.comRetail investors who hold 38% of MediWound Ltd. (NASDAQ:MDWD) gained 15%, institutions profited as wellFebruary 23, 2024 | msn.comNexobrid: A revolutionary treatment for burns to treat patients in few hoursFebruary 12, 2024 | marketwatch.comMediWound Shares Climb on Positive Data for EscharExFebruary 12, 2024 | markets.businessinsider.comMediWound Reports Positive Results In Head-to-head Comparison Of EscharEx Vs SANTYLFebruary 12, 2024 | finance.yahoo.comMediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled StudySee More Headlines Receive MDWD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today6/01/2024Next Earnings (Estimated)8/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medicinals & botanicals Sub-IndustryN/A Current SymbolNASDAQ:MDWD CUSIPN/A CIK1593984 Webwww.mediwound.com Phone972779714100Fax972-77-971-4111Employees100Year Founded2001Price Target and Rating Average Stock Price Target$32.00 High Stock Price Target$36.00 Low Stock Price Target$28.00 Potential Upside/Downside+96.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,720,000.00 Net Margins-64.24% Pretax Margin-63.21% Return on Equity-21.67% Return on Assets-10.23% Debt Debt-to-Equity RatioN/A Current Ratio1.98 Quick Ratio4.33 Sales & Book Value Annual Sales$19.85 million Price / Sales7.63 Cash FlowN/A Price / Cash FlowN/A Book Value$2.50 per share Price / Book6.52Miscellaneous Outstanding Shares9,284,000Free Float8,619,000Market Cap$151.42 million OptionableOptionable Beta0.81 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Ofer Gonen B.Sc. (Age 51)Chief Executive Officer Comp: $649kMs. Hani Luxenburg (Age 51)Chief Financial Officer Comp: $235kMr. Yaron Meyer Adv. (Age 45)Executive VP, General Counsel & Corporate Secretary Comp: $299kDr. Ety Klinger MBA (Age 62)Ph.D., Chief Research & Development Officer Comp: $377kDr. Lior Rosenberg M.D. (Age 78)Co-Founder Comp: $727kDr. Shmulik Hess Ph.D. (Age 51)COO & Chief Commercial Officer Mr. Barry J. Wolfenson (Age 57)Executive Vice President of Strategy & Corporate Development Dr. Robert J. Snyder CWS (Age 74)D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc., Chief Medical Officer More ExecutivesKey CompetitorsMenlo TherapeuticsNASDAQ:FOMXMind Medicine (MindMed)NASDAQ:MNMDbioteNASDAQ:BTMDSNDLNASDAQ:SNDLAurora CannabisNASDAQ:ACBView All CompetitorsInstitutional OwnershipEssex Investment Management Co. LLCBought 93,705 shares on 5/3/2024Ownership: 1.396%Janney Montgomery Scott LLCBought 29,948 shares on 5/1/2024Ownership: 0.316%Rosalind Advisors Inc.Sold 120,761 shares on 4/25/2024Ownership: 5.121%Silverberg Bernstein Capital Management LLCBought 6,200 shares on 4/11/2024Ownership: 0.898%View All Institutional Transactions MDWD Stock Analysis - Frequently Asked Questions Should I buy or sell MediWound stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MDWD shares. View MDWD analyst ratings or view top-rated stocks. What is MediWound's stock price target for 2024? 2 equities research analysts have issued 1-year target prices for MediWound's stock. Their MDWD share price targets range from $28.00 to $36.00. On average, they expect the company's share price to reach $32.00 in the next year. This suggests a possible upside of 96.2% from the stock's current price. View analysts price targets for MDWD or view top-rated stocks among Wall Street analysts. How have MDWD shares performed in 2024? MediWound's stock was trading at $10.17 at the start of the year. Since then, MDWD stock has increased by 60.4% and is now trading at $16.31. View the best growth stocks for 2024 here. When is MediWound's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 20th 2024. View our MDWD earnings forecast. How were MediWound's earnings last quarter? MediWound Ltd. (NASDAQ:MDWD) announced its quarterly earnings results on Thursday, March, 21st. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.04. The biopharmaceutical company earned $5.34 million during the quarter, compared to the consensus estimate of $5.33 million. MediWound had a negative net margin of 64.24% and a negative trailing twelve-month return on equity of 21.67%. When did MediWound's stock split? MediWound shares reverse split on the morning of Tuesday, December 20th 2022. The 1-7 reverse split was announced on Tuesday, December 20th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. What other stocks do shareholders of MediWound own? Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), Blackstone (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC). Who are MediWound's major shareholders? MediWound's stock is owned by a number of institutional and retail investors. Top institutional investors include Rosalind Advisors Inc. (5.12%), Essex Investment Management Co. LLC (1.40%), Silverberg Bernstein Capital Management LLC (0.90%) and Janney Montgomery Scott LLC (0.32%). How do I buy shares of MediWound? Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MDWD) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProDems have chosen Biden replacement?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is about to pass AppleWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediWound Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
